Terms: = Leukemia AND IKZF1, LyF-1, 10320, ENSG00000185811, Q13422, Hs_54452, hIk-1, ZNFN1A1, IKAROS
605 results:
1. [The value of minimal residual disease and ikzf1 deletion for predicting prognosis in adult patients with B-cell acute lymphoblastic leukemia].
Deng SY; Ou JW; Huang ZC; Chen JJ; Cai ZH; Liu QF; Zhou HS
Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):257-263. PubMed ID: 38716597
[No Abstract] [Full Text] [Related]
2. Shared genetic architecture between autoimmune disorders and B-cell acute lymphoblastic leukemia: insights from large-scale genome-wide cross-trait analysis.
Yu X; Chen Y; Chen J; Fan Y; Lu H; Wu D; Xu Y
BMC Med; 2024 Apr; 22(1):161. PubMed ID: 38616254
[TBL] [Abstract] [Full Text] [Related]
3. Extracellular matrix protein 1 (ECM1) is a potential biomarker in B cell acute lymphoblastic leukemia.
Wu LX; Zhao MY; Yan N; Zhou YL; Cao LM; Qin YZ; Jiang Q; Xu LP; Zhang XH; Huang XJ; Jiang H; Ruan GR
Clin Exp Med; 2024 Mar; 24(1):56. PubMed ID: 38546916
[TBL] [Abstract] [Full Text] [Related]
4. A noncoding regulatory variant in ikzf1 increases acute lymphoblastic leukemia risk in Hispanic/Latino children.
de Smith AJ; Wahlster L; Jeon S; Kachuri L; Black S; Langie J; Cato LD; Nakatsuka N; Chan TF; Xia G; Mazumder S; Yang W; Gazal S; Eng C; Hu D; Burchard EG; Ziv E; Metayer C; Mancuso N; Yang JJ; Ma X; Wiemels JL; Yu F; Chiang CWK; Sankaran VG
Cell Genom; 2024 Apr; 4(4):100526. PubMed ID: 38537633
[TBL] [Abstract] [Full Text] [Related]
5. Refining risk stratification in paediatric B-acute lymphoblastic leukaemia: Combining ikzf1
Liu HC; Huang YJ; Jaing TH; Wu KH; Chen SH; Wang SC; Yeh TC; Hsiao CC; Chang TK; Yen HJ; Huang FL; Lin PC; Hou JY; Sheen JM; Liao YM; Chang TY; Chen YC; Chiou SS; Yang CP; Pui CH; Liang DC; Shih LY
Br J Haematol; 2024 Apr; 204(4):1344-1353. PubMed ID: 38479427
[TBL] [Abstract] [Full Text] [Related]
6. KCTD5 regulates ikaros degradation induced by chemotherapeutic drug etoposide in hematological cells.
Ma L; Yin C; Zhang Y; Li J; Shi L; Zhou T; Huang X; Liu Y; Cao J; Wu G; Gu H; He L
Biol Chem; 2024 May; 405(5):341-349. PubMed ID: 38424700
[TBL] [Abstract] [Full Text] [Related]
7. Tyrosine kinase inhibitor resistance in de novo BCR::ABL1-positive BCP-ALL beyond kinase domain mutations.
van Outersterp I; Boer JM; van de Ven C; Reichert CEJ; Boeree A; Kruisinga B; de Groot-Kruseman HA; Escherich G; Sijs-Szabo A; Rijneveld AW; den Boer ML
Blood Adv; 2024 Apr; 8(8):1835-1845. PubMed ID: 38386975
[TBL] [Abstract] [Full Text] [Related]
8. Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and ikzf1/3 degrader NX-2127.
Montoya S; Bourcier J; Noviski M; Lu H; Thompson MC; Chirino A; Jahn J; Sondhi AK; Gajewski S; Tan YSM; Yung S; Urban A; Wang E; Han C; Mi X; Kim WJ; Sievers Q; Auger P; Bousquet H; Brathaban N; Bravo B; Gessner M; Guiducci C; Iuliano JN; Kane T; Mukerji R; Reddy PJ; Powers J; Sanchez Garcia de Los Rios M; Ye J; Barrientos Risso C; Tsai D; Pardo G; Notti RQ; Pardo A; Affer M; Nawaratne V; Totiger TM; Pena-Velasquez C; Rhodes JM; Zelenetz AD; Alencar A; Roeker LE; Mehta S; Garippa R; Linley A; Soni RK; Skånland SS; Brown RJ; Mato AR; Hansen GM; Abdel-Wahab O; Taylor J
Science; 2024 Feb; 383(6682):eadi5798. PubMed ID: 38301010
[TBL] [Abstract] [Full Text] [Related]
9. [Suspicion of constitutional abnormality at diagnosis of childhood leukemia: Update of the leukemia committee of the French Society of Childhood Cancers].
Strullu M; Cousin E; de Montgolfier S; Fenwarth L; Gachard N; Arnoux I; Duployez N; Girard S; Guilmatre A; Lafage M; Loosveld M; Petit A; Perrin L; Vial Y; Saultier P
Bull Cancer; 2024 Mar; 111(3):291-309. PubMed ID: 38267311
[TBL] [Abstract] [Full Text] [Related]
10. Combination of minimal residual disease on day 15 and copy number alterations results in BCR-ABL1-negative pediatric B-ALL: A powerful tool for prediction of induction failure.
Baghdadi H; Soleimani M; Zavvar M; Bahoush G; Poopak B
Cancer Genet; 2024 Apr; 282-283():27-34. PubMed ID: 38183785
[TBL] [Abstract] [Full Text] [Related]
11. Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL.
Bastian L; Beder T; Barz MJ; Bendig S; Bartsch L; Walter W; Wolgast N; Brändl B; Rohrandt C; Hansen BT; Hartmann AM; Iben K; Das Gupta D; Denker M; Zimmermann J; Wittig M; Chitadze G; Neumann M; Schneller F; Fiedler W; Steffen B; Stelljes M; Faul C; Schwartz S; Müller FJ; Cario G; Harder L; Haferlach C; Pfeifer H; Gökbuget N; Brüggemann M; Baldus CD
Blood; 2024 Apr; 143(14):1391-1398. PubMed ID: 38153913
[TBL] [Abstract] [Full Text] [Related]
12. DNA Copy Number Alterations and Copy Neutral Loss of Heterozygosity in Adult Ph-Negative Acute B-Lymphoblastic leukemia: Focus on the Genes Involved.
Risinskaya N; Gladysheva M; Abdulpatakhov A; Chabaeva Y; Surimova V; Aleshina O; Yushkova A; Dubova O; Kapranov N; Galtseva I; Kulikov S; Obukhova T; Sudarikov A; Parovichnikova E
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139431
[TBL] [Abstract] [Full Text] [Related]
13. Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL.
Foà R; Bassan R; Elia L; Piciocchi A; Soddu S; Messina M; Ferrara F; Lunghi M; Mulè A; Bonifacio M; Fracchiolla N; Salutari P; Fazi P; Guarini A; Rambaldi A; Chiaretti S
J Clin Oncol; 2024 Mar; 42(8):881-885. PubMed ID: 38127722
[No Abstract] [Full Text] [Related]
14. Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML.
Bourgeois W; Cutler JA; Aubrey BJ; Wenge DV; Perner F; Martucci C; Henrich JA; Klega K; Nowak RP; Donovan KA; Boileau M; Wen Y; Hatton C; Apazidis AA; Olsen SN; Kirmani N; Pikman Y; Pollard JA; Perry JA; Sperling AS; Ebert BL; McGeehan GM; Crompton BD; Fischer ES; Armstrong SA
Blood; 2024 Apr; 143(15):1513-1527. PubMed ID: 38096371
[TBL] [Abstract] [Full Text] [Related]
15. Design and Development of IKZF2 and CK1α Dual Degraders.
Miyamoto DK; Curnutt NM; Park SM; Stavropoulos A; Kharas MG; Woo CM
J Med Chem; 2023 Dec; 66(24):16953-16979. PubMed ID: 38085607
[TBL] [Abstract] [Full Text] [Related]
16. IKZF3 polymorphisms contribute to the increased risk of acute lymphoblastic leukemia in children.
Yang X; Yang L; Luo A; Liu S; Zhang X; Liu X; Liu X; Luo A; Cai M; Yan Y; Wu X; Huang K; Xu L; Jiang H
Cancer; 2024 Mar; 130(6):973-984. PubMed ID: 38018448
[TBL] [Abstract] [Full Text] [Related]
17. Transcriptome Sequencing Allows Comprehensive Genomic Characterization of Pediatric B-Acute Lymphoblastic leukemia in an Academic Clinical Laboratory.
Hu Z; Kovach AE; Yellapantula V; Ostrow D; Doan A; Ji J; Schmidt RJ; Gu Z; Bhojwani D; Raca G
J Mol Diagn; 2024 Jan; 26(1):49-60. PubMed ID: 37981088
[TBL] [Abstract] [Full Text] [Related]
18. Genomic Mutation Profiles of Patients with Acute Myeloid leukemia in Korea: a Single-Center Experience.
Han E; Ryu S; Kim D; Koh EH; Byun JH; Lee DH
Clin Lab; 2023 Nov; 69(11):. PubMed ID: 37948498
[TBL] [Abstract] [Full Text] [Related]
19. The clinical features and prognostic implications of PTPN11 mutation in adult patients with acute myeloid leukemia in China.
Yang J; Zhao L; Wu Y; Niu T; Gong Y; Chen X; Huang X; Liu J; Dai Y; Ma H
Cancer Med; 2023 Dec; 12(23):21111-21117. PubMed ID: 37937729
[TBL] [Abstract] [Full Text] [Related]
20. Pre- and Postnatal Exposures to Tobacco Smoking and Survival of Childhood Acute Lymphoblastic and Myeloid leukemias in California, United States.
Metayer C; Morimoto LM; Kang AY; Sanchez Alvarez J; Winestone LE
Cancer Epidemiol Biomarkers Prev; 2024 Jan; 33(1):117-125. PubMed ID: 37921440
[TBL] [Abstract] [Full Text] [Related]
[Next]
